Categories: All postsCannabis

The Valens Company gets new “Buy” rating at Stifel

Stifel GMP has launched coverage of Canadian cannabis extraction company The Valens Company (The Valens Company Stock Quote, Chart, News TSX:VLNS), with Stifel analyst Andrew Partheniou opening coverage on Thursday with a “Buy” rating and $3.75 target price. Partheniou said Valens’ proven track record of execution and considerable runway up ahead, the company is positioned for sustainable profitability.

Kelowna, BC-based Valens was founded in 2012 and is one of the largest extractors and manufacturers in Canada, with a wide selection of extraction methods and cannabis 2.0 products. Valens has about 425 tonnes of biomass extraction capacity at its Kelowna facility and offers both tolling services for processing a customer’s biomass or the sale of bulk extracts to the wholesale market. Valens has a second facility in development for expansion into EU-GMP standards for its 2.0 products, with construction to be completed over the second half of 2020.

Partheniou figures the total addressable market for extract retail could reach about $2 billion by the end of 2021. Extracts currently represent about 24 per cent of overall industry sales but the segment is in the early innings, according to the analyst, who estimated penetration could reach about 45 per cent, which could more than triple Valens’ market from second quarter 2020 levels to about $2 billion by the end of 2021.

“VLNS stands out among its peers with its flexibility to produce every 2.0 product format available thereby maximizing its utility to brand partners/LPs. In addition, the company has a proven track-record of execution through launching the first cannabis beverage into the REC channel and a history of robust profitability,” Partheniou wrote.

As well, Partheniou pointed to the current glut of cannabis flower in Canada, which makes for a ripe opportunity for extractors like Valens —the analyst estimates there could be as much as 325 tonnes of dried flower oversupply currently sitting in LPs’ inventories, with potentially more stored away after this fall’s outdoor harvest. All told, this could make for a new $275 to $300 million in tolling revenue opportunity for Canadian extractors.

“With VLNS currently having products in the REC market spanning nearly every 2.0 product category, VLNS has established a strong start to its REC presence. In addition, we believe that as its edible manufacturing facility comes online, VLNS could further expand upon its already fulsome product portfolio,” Partheniou wrote.

On the numbers, Partheniou thinks Valens will generate revenue and EBITDA in fiscal 2020 (year end Nov 30) of $88.1 million and $20.0 million, respectively, and revenue and EBITDA in fiscal 2021 of $143.4 million and $37.1 million, respectively.

At press time, his $3.75 target represented a projected one-year return of 92.3 per cent. Year-to-date,
VLNS is currently down 45 per cent.

Valens last reported earnings on July 15 where its second quarter 2020 featured revenue of $17.6 million compared to $8.8 million a year earlier and adjusted EBITDA of $2.7 million or 15.3 per cent of revenue compared to $2.0 million or 23.0 per cent of revenue in Q2 2019.

We Hate Paywalls Too!

At Cantech Letter we prize independent journalism like you do. And we don't care for paywalls and popups and all that noise That's why we need your support. If you value getting your daily information from the experts, won't you help us? No donation is too small.

Make a one-time or recurring donation

Tagged with: vlns
Jayson MacLean

Jayson is a writer, researcher and educator with a PhD in political philosophy from the University of Ottawa. His interests range from bioethics and innovations in the health sciences to governance, social justice and the history of ideas.

Recent Posts

EGLX has price target slashed at Haywood

Following the company's first quarter results, Haywood analyst Gianluca Tucci has cut his price target on Enthusiast Gaming (Enthusiast Gaming… [Read More]

23 hours ago

Is Dexterra Group a buy?

Its first quarter results are in the books and Beacon analyst Kirk Wilson has lowered his price target on Dexterra… [Read More]

1 day ago

Is AYR stock a buy?

Following the company's first quarter results, Beacon analyst Russell Stanley has maintained his "Buy" rating on Ayr Wellness (Ayr Wellness… [Read More]

2 days ago

Cresco Labs earns target raise at Echelon

Following the company's first quarter results, Echelon Capital Markets analyst Andrew Semple has raised his price target on Cresco Labs… [Read More]

2 days ago

SSTI is a buy, Roth says

Its first quarter results are in the book and Roth MKM analyst Richard K Baldry is still bullish on SoundThinking… [Read More]

3 days ago

GLXY wins price target raise at ATB Capital

Following the company's first quarter results, ATB Capital Markets analyst Martin Toner has raised his price target on Galaxy Digital… [Read More]

3 days ago